What is Amplicore?
Amplicore is a specialized biotechnology firm dedicated to the development of injectable therapeutics designed to combat degenerative musculoskeletal disorders. The company's core focus encompasses the treatment of osteoarthritis, cartilage damage, degenerative disc disease, and acute meniscus tears. By leveraging a regenerative medicine framework, Amplicore aims to provide minimally invasive, highly effective solutions that restore joint function and alleviate chronic pain. Their market position is defined by a commitment to translating complex scientific innovation into practical, clinician-friendly products that address significant unmet needs in the global healthcare market.
How much funding has Amplicore raised?
Amplicore has raised a total of $4M across 1 funding round:
Angel/Seed
$4M
Angel/Seed (2021): $4M with participation from The Photonics Fund, Berkeley Catalyst Fund, SVE Capital, and Industrial Technology Investment
Key Investors in Amplicore
SVE Capital
SVE Capital is a specialized resource firm focused on supporting early-stage ventures within the life sciences sector, providing essential guidance for navigating industry complexities.
Industrial Technology Investment
The Industrial Technology Investment Corporation acts as the venture capital arm of the Industrial Technology Research Institute, leveraging extensive R&D resources to foster growth in innovative startups.
The Photonics Fund
The Photonics Fund is a venture capital and private equity firm that provides strategic financial backing to emerging companies, contributing to the broader innovation ecosystem.
What's next for Amplicore?
Looking ahead, Amplicore is poised to utilize this recent capital to scale its R&D operations and advance its lead candidates through critical regulatory milestones. The strategic focus will likely center on expanding clinical trial capacity and refining manufacturing processes to ensure scalability. As the company matures, the emphasis will shift toward establishing commercial partnerships and navigating the complex regulatory pathways required for market entry. With the support of its current investor base, Amplicore is strategically aligned to disrupt the traditional orthopedic treatment paradigm, potentially setting a new standard for regenerative joint care in the coming years.
See full Amplicore company page
